EGFR-mutant tumors exhibit an increased response rate to tyrosine kinase inhibitors (TKIs) versus EGFR wild-type tumors (7), while cisplatin-based chemotherapy yields more optimal outcomes in patients with EGFR wild-type lung cancer (8). This evidence concerns the gene EGFR and lung cancer.